Prognostic factors of patients with acute myeloid leukemia (AML) allografted in first complete remission: an analysis of the EORTC-GIMEMA AML 8A trial

There is no fulltext present in this item.

Title:	Prognostic factors of patients with acute myeloid leukemia (AML) allografted in first complete remission: an analysis of the EORTC-GIMEMA AML 8A trial
Author(s):	Keating, S. ; Suciu, S.; Witte, T.J.M. de ; Mandelli, F.; Willemze, R.; Resegotti, L.; Broccia, G.; Thaler, J.; Labar, B.; Damasio, E.; Bizzi, B.; Rotoli, B.; Vekhoff, A.; Muus, P. ; Petti, M.C.; Dardenne, M.; Solbu, G.; Vegna, M.L.; Zittoun, R.
Publication year:	1996
Source:	Bone Marrow Transplantation, vol. IV, (1996), pp. 993-1001
ISSN:	0268-3369
Publication type:	Article / Letter to editor
Please use this identifier to cite or link to this item : https://hdl.handle.net/2066/189278
Display more details
Subject:	European evaluation of intensive antileukemic therapy for patients with myelodysplastic syndrome (MDS) CRIANT: clonal remission after intensive antileukemic therapy (Biomed-2 1995)
Organization:	Haematology
Journal title:	Bone Marrow Transplantation
Volume:	vol. IV
Page start:	p. 993
Page end:	p. 1001